Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 in neovascular age-related macular degeneration
NCT07275840Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
A Phase 2 trial of efdamrofusp alfa in neovascular age-related macular degeneration (NVAMD), sponsored by Innovent Biologics. Started Dec 2025; status: recruiting.
02
Drugs
efdamrofusp alfa
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07275840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275840.